Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Briquilimab Biologics Sequence Review Report 2026: KIT Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Briquilimab, an antibody targeting KIT.
Read →
Latest Hotspot
8 min read
Izeltabart Biologics Sequence Review Report 2026: ADAM9 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izeltabart, an antibody targeting ADAM9.
Read →
Latest Hotspot
8 min read
Pamvatamig Biologics Sequence Review Report 2026: MET × EGFR Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamvatamig, an antibody targeting MET × EGFR.
Read →
Latest Hotspot
8 min read
Bezetabart Biologics Sequence Review Report 2026: CD74 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bezetabart, an antibody targeting CD74.
Read →
Latest Hotspot
8 min read
Teneliximab Biologics Sequence Review Report 2026: TNFRSF5 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teneliximab, an antibody targeting TNFRSF5.
Read →
Latest Hotspot
8 min read
Sonavibart Biologics Sequence Review Report 2026: Influenza A HA Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sonavibart, an antibody targeting Influenza A HA.
Read →
Latest Hotspot
8 min read
Danvilostomig Biologics Sequence Review Report 2026: CTLA-4 × PD-1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Danvilostomig, an antibody targeting CTLA-4 × PD-1.
Read →
Latest Hotspot
8 min read
Lintuzumab Biologics Sequence Review Report 2026: SIGLEC3 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lintuzumab, an antibody targeting SIGLEC3.
Read →
Latest Hotspot
8 min read
Erlizumab Biologics Sequence Review Report 2026: ITGB2 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erlizumab, an antibody targeting ITGB2.
Read →
Latest Hotspot
8 min read
Metelimumab Biologics Sequence Review Report 2026: TGF-beta1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Metelimumab, an antibody targeting TGF-beta1.
Read →
Latest Hotspot
8 min read
Matuzumab Biologics Sequence Review Report 2026: EGFR Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Matuzumab, an antibody targeting EGFR.
Read →
Latest Hotspot
8 min read
Fontolizumab Biologics Sequence Review Report 2026: IFNG Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fontolizumab, an antibody targeting IFNG.
Read →
<
1
2
3
4
5
>>
1110
>